Characterization of Naturally Occurring Bioactive Factor Mixtures for Bone Regeneration.
Adipose Tissue
/ chemistry
Adult
Angiogenesis Inducing Agents
/ chemistry
Bone Regeneration
/ drug effects
Cell Hypoxia
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cells, Cultured
Chemokine CCL2
/ metabolism
Culture Media, Conditioned
/ chemistry
Cytokines
/ metabolism
Female
Human Umbilical Vein Endothelial Cells
Humans
Insulin-Like Growth Factor Binding Protein 1
/ metabolism
Intercellular Signaling Peptides and Proteins
/ metabolism
Male
Mesenchymal Stem Cells
/ drug effects
Middle Aged
Neovascularization, Physiologic
/ drug effects
Osteogenesis
/ drug effects
Platelet-Rich Plasma
/ chemistry
Protein Array Analysis
Ribonuclease, Pancreatic
/ metabolism
adipose tissue extract
bone regeneration
growth factor
hypoxia-conditioned medium
platelet lysates
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Feb 2020
19 Feb 2020
Historique:
received:
24
01
2020
revised:
11
02
2020
accepted:
13
02
2020
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
5
1
2021
Statut:
epublish
Résumé
In this study, the bone-regenerative potential of bioactive factors derived from adipose tissue, platelet-rich plasma (PRP) and conditioned medium from hypoxia-treated human telomerase immortalized bone-marrow-derived mesenchymal stem cells (hTERT-MSC) was investigated in vitro with the aim to develop cost-effective and efficient bone substitutes for optimized regeneration of bone defects. Adipose tissue was harvested from human donors undergoing reconstructive surgery, and adipose tissue extract (ATE) was prepared. Platelet lysates (PL) were produced by repeated freeze-thaw cycles of PRP, and hypoxia-conditioned medium (HCM) was obtained by culturing human telomerase immortalized bone-marrow-derived mesenchymal stromal cells for 5 days with 1% O2. Besides analysis by cytokine and angiogenesis arrays, ELISA was performed. Angiogenic potential was investigated in cocultures of bone-marrow-derived (BM)-MSC and human umbilical vein endothelial cells. Multiple angiogenic proteins and cytokines were detected in all growth factor mixtures. HCM and ATE contained high amounts of angiogenin and CCL2/MCP-1, whereas PL contained high amounts of IGFBP-1. Culturing cells with HCM and ATE significantly increased specific ALP activity of BM-MSC as well as tubule length and junctions of endothelial networks, indicating osteogenic and angiogenic stimulation. To achieve a synergism between chemoattractive potential and osteogenic and angiogenic differentiation capacity, a combination of different growth factors appears promising for potential clinical applications.
Identifiants
pubmed: 32093051
pii: ijms21041412
doi: 10.3390/ijms21041412
pmc: PMC7073126
pii:
doi:
Substances chimiques
Angiogenesis Inducing Agents
0
CCL2 protein, human
0
Chemokine CCL2
0
Culture Media, Conditioned
0
Cytokines
0
IGFBP1 protein, human
0
Insulin-Like Growth Factor Binding Protein 1
0
Intercellular Signaling Peptides and Proteins
0
angiogenin
EC 3.1.27.-
Ribonuclease, Pancreatic
EC 3.1.27.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : TRR 67 - B05 Projektnummer 125378466
Organisme : Deutsche Forschungsgemeinschaft
ID : TRR 79 - M04 Projektnummer 170599561
Organisme : Roland Ernst Stiftung
ID : Dresden, Germany
Références
Tissue Eng Part A. 2012 Jan;18(1-2):17-25
pubmed: 21902602
J Tissue Eng Regen Med. 2015 Apr;9(4):447-59
pubmed: 24764222
Biomaterials. 2004 Oct;25(23):5387-93
pubmed: 15130723
Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83
pubmed: 10708863
Curr Top Microbiol Immunol. 2014;380:157-90
pubmed: 25004818
Acta Biomater. 2018 Jan;65:475-485
pubmed: 29107056
Eur J Med Res. 2004 Jul 30;9(7):337-44
pubmed: 15337634
Bone. 2007 Feb;40(2):522-8
pubmed: 17070744
Exp Cell Res. 2014 Mar 10;322(1):62-70
pubmed: 24394542
J Cell Physiol. 2011 Feb;226(2):385-96
pubmed: 20665704
Biores Open Access. 2016 Sep 01;5(1):269-78
pubmed: 27679753
J Bone Joint Surg Am. 1997 May;79(5):756-9
pubmed: 9160949
Int Orthop. 2014 Sep;38(9):2001-7
pubmed: 24627122
Science. 1994 Apr 1;264(5155):90-2
pubmed: 8140420
Eur Cell Mater. 2017 Feb 09;33:105-120
pubmed: 28181209
Thromb Haemost. 2003 Mar;89(3):573-82
pubmed: 12624643
J Bone Joint Surg Am. 2007 Mar;89(3):649-58
pubmed: 17332116
Stem Cell Res Ther. 2018 Oct 11;9(1):265
pubmed: 30305185
Int J Biol Sci. 2012;8(9):1237-47
pubmed: 23136552
Stem Cells Int. 2019 Oct 31;2019:1234263
pubmed: 31781232
Endocr Rev. 1997 Dec;18(6):801-31
pubmed: 9408744
Biochim Biophys Acta. 2011 May;1813(5):878-88
pubmed: 21296109
Orthopedics. 2017 Mar 1;40(2):e229-e237
pubmed: 27992640
Mol Pain. 2013 Mar 28;9:16
pubmed: 23537341
J Cell Mol Med. 2008 Aug;12(4):1347-59
pubmed: 18318690
Endocrinology. 2012 May;153(5):2296-310
pubmed: 22492305
Med Mol Morphol. 2014 Jun;47(2):83-9
pubmed: 23604952
Mol Oncol. 2014 May;8(3):483-507
pubmed: 24457100
J Orthop Case Rep. 2015 Jul-Sep;5(3):18-21
pubmed: 27299059
J Orthop Surg Res. 2017 Nov 21;12(1):178
pubmed: 29157270
Biomatter. 2012 Jul-Sep;2(3):132-41
pubmed: 23507864
Diabetes Metab. 2004 Feb;30(1):13-9
pubmed: 15029093
Foot Ankle Int. 2006 Jul;27(7):561-6
pubmed: 16842727
Exp Cell Res. 2006 Mar 10;312(5):527-37
pubmed: 16330026
J Immunol. 2003 Mar 15;170(6):3369-76
pubmed: 12626597
Microvasc Res. 2013 Sep;89:15-24
pubmed: 23660186
Curr Med Chem. 2013;20(20):2501-23
pubmed: 23521682
Unfallchirurg. 2012 Oct;115(10):938-49
pubmed: 22821191
Tissue Eng Part A. 2014 Oct;20(19-20):2614-33
pubmed: 24666439
BMC Vet Res. 2014 Mar 04;10:56
pubmed: 24593914
Dent Clin North Am. 2015 Apr;59(2):493-503
pubmed: 25835805
Physiol Rev. 1999 Oct;79(4):1283-316
pubmed: 10508235
Oncol Rep. 2017 Jul;38(1):21-30
pubmed: 28560447
Biomed Res Int. 2014;2014:781632
pubmed: 25093183
Strategies Trauma Limb Reconstr. 2016 Apr;11(1):53-8
pubmed: 26984411
Biofabrication. 2018 Jul 27;10(4):045002
pubmed: 30004388
Circulation. 2004 Mar 16;109(10):1292-8
pubmed: 14993122
Cytokine Growth Factor Rev. 2014 Feb;25(1):1-19
pubmed: 24332926
J Tissue Eng. 2017 Apr 24;8:2041731417704791
pubmed: 28491274
Sci Rep. 2016 Sep 14;6:33123
pubmed: 27625115
Int Immunopharmacol. 2013 Jun;16(2):214-23
pubmed: 23587487
Tissue Eng Part B Rev. 2016 Aug;22(4):284-97
pubmed: 26857241
J Tissue Eng. 2010 Nov 07;2010:218142
pubmed: 21350642
PLoS One. 2014 Apr 29;9(4):e96161
pubmed: 24781370
J Orthop Res. 2019 Jun;37(6):1318-1328
pubmed: 30628121
Cell Med. 2017 Apr 14;9(3):103-116
pubmed: 28713640
Acta Biomater. 2017 Nov;63:1-17
pubmed: 28941652
Eur J Cell Biol. 1997 Oct;74(2):111-22
pubmed: 9352216
Tissue Eng Part A. 2013 Nov;19(21-22):2495-505
pubmed: 23901900
Biofactors. 2014 Sep-Oct;40(5):459-81
pubmed: 25283434
Cytotechnology. 2018 Aug;70(4):1193-1204
pubmed: 29511946
Materials (Basel). 2012 Mar 22;5(3):540-557
pubmed: 28817062
Tissue Eng Part A. 2012 Dec;18(23-24):2568-80
pubmed: 22738319
Annu Rev Biochem. 2006;75:367-401
pubmed: 16756496
Tissue Eng Part A. 2012 Jul;18(13-14):1479-89
pubmed: 22443121